VUITY® | ECP Allergan

For US Healthcare Professionals Only

The
first and only FDA-approved eye drop specifically designed for presbyopia.^1,2 A daily treatment for mild-to-moderate
patients with presbyopia.^1,3

FDA-approved eye drop
specifically designed for presbyopia.^1,2
A daily treatment
for mild-to-moderate patients
with presbyopia.^1,3

FDA-approved eye drop
specifically designed for presbyopia.^1,2
A daily treatment
for mild-to-moderate patients
with presbyopia.^1,3

Reengineered Formulation

Designed to balance

efficacy, safety, and tolerability^1,2

VUITY (pilocarpine HCI ophthalmic solution) 1.25%

Delivered with pHast^TM technology Rapidly adjusts to physiologic pH*⁴

*In vitro data. Clinical significance is unknown.
The pH range in the bottle is between 3.5 and 5.5.¹

*In vitro data. Clinical significance is unknown. The pH range in the bottle is between 3.5 and 5.5.¹

See how VUITY® works

Improved near and intermediate vision without compromising
distance vision^1,5

Primary endpoint was the proportion of patients gaining ≥3 lines in mesopic, high-contrast, binocular distance-corrected near visual acuity (DCNVA) without losing more than 1 line (5 letters) of corrected distance visual acuity (CDVA) with the same refractive correction at Day 30, Hour 3.¹

Change from baseline in photopic, high-contrast, binocular distance-corrected intermediate visual acuity (DCIVA) at Day 30, Hour 3 was a prespecified secondary endpoint.⁵

Learn more about efficacy

One drop going into a puddle

VUITY® has a well-established safety and tolerability profile in clinical trials¹

Learn more about safety

NEARLY 9/10

Trial participants [N=76] surveyed would ask their eye doctor for VUITY®^†6

†Assessed by a survey in a subset of participants in the VUITY® arm of GEMINI 1 and GEMINI 2 studies.

Not an actual patient

What we heard from trial participants^‡

Actual participants not shown.

“These eye drops provided me another option for how I manage my presbyopia.”

^‡The GEMINI 1 and GEMINI 2 trials were double masked, and during the trials the participants did not know if they were on treatment or vehicle.

Actual participants not shown.

“These eye drops helped me to see up close without compromising my distance vision.”

^‡The GEMINI 1 and GEMINI 2 trials were double masked, and during the trials the participants did not know if they were on treatment or vehicle.

Actual participants not shown.

“Taking an eye drop once daily is convenient.”

^‡The GEMINI 1 and GEMINI 2 trials were double masked, and during the trials the participants did not know if they were on treatment or vehicle.

Actual participants not shown.

“I don’t always want to wear reading glasses and these drops don’t change my look.”

^‡The GEMINI 1 and GEMINI 2 trials were double masked, and during the trials the participants did not know if they were on treatment or vehicle.

Actual participants not shown.

“I used my reading
glasses less.^§”

^‡The GEMINI 1 and GEMINI 2 trials were double masked, and during the trials the participants did not know if they were on treatment or vehicle.
^§Use of reading glasses was not permitted at study visits during the trials.

How to get your patients with presbyopia started

Learn more about prescribing

Ready to

take a closer look

at VUITY®?

Request a Rep

INDICATION

VUITY® (pilocarpine hydrochloride ophthalmic solution) 1.25% is indicated for the treatment of presbyopia in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS AND PRECAUTIONS

Miotics, including VUITY, may cause accommodative spasm. Patients should be advised not to drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics, including VUITY. Patients should be advised to exercise caution in night driving and other hazardous activities in poor illumination.

Rare cases of retinal detachment and retinal tear have been reported with miotics, including VUITY. Individuals with pre-existing retinal disease are at increased risk. Therefore, examination of the retina is advised in all patients prior to the initiation of therapy. Patients should be advised to seek immediate medical care with sudden onset of flashing lights, floaters, or vision loss.

VUITY is not recommended to be used when iritis is present because adhesions (synechiae) may form between the iris and lens.

Contact lens wearers should be advised to remove their lenses prior to the instillation of VUITY and to wait 10 minutes after dosing before reinserting their contact lenses.

To prevent eye injury or contamination, care should be taken to avoid touching the dispensing bottle to the eye or to any other surface.

ADVERSE REACTIONS

The most common adverse reactions (>5%) reported in clinical trials were headache, conjunctival hyperemia, and eye irritation.

Please see full Prescribing Information.

US-VUI-230052

AEs: adverse events. CDVA: corrected distance visual acuity. DCIVA: distance corrected intermediate visual acuity. DCNVA: distance corrected near visual acuity. FDA: Food and Drug administration.

References: 1. VUITY [package insert]. North Chicago, IL: AbbVie Inc. 2. Price FW, et al. Ophthalmol Sci. 2021; doi: https://doi.org/10.1016/j.xops.2021.100065. 3. Data on File, ABVRRTI73149. 4. Data on File, ABVRRTI73125.5. Data on File, ABVRRTI73127.6. Data on File, REF-87081.

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS AND PRECAUTIONS

Miotics, including VUITY, may cause accommodative spasm. Patients should be advised not to drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics, including VUITY. Patients should be advised to exercise caution in night driving and other hazardous activities in poor illumination.

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS AND PRECAUTIONS

Miotics, including VUITY, may cause accommodative spasm. Patients should be advised not to drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics, including VUITY. Patients should be advised to exercise caution in night driving and other hazardous activities in poor illumination.

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS AND PRECAUTIONS

Miotics, including VUITY, may cause accommodative spasm. Patients should be advised not to drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics, including VUITY. Patients should be advised to exercise caution in night driving and other hazardous activities in poor illumination.

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS AND PRECAUTIONS

Miotics, including VUITY, may cause accommodative spasm. Patients should be advised not to drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics, including VUITY. Patients should be advised to exercise caution in night driving and other hazardous activities in poor illumination.

INDICATION

VUITY® (pilocarpine hydrochloride ophthalmic solution) 1.25% is indicated for the treatment of presbyopia in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS AND PRECAUTIONS

Miotics, including VUITY, may cause accommodative spasm. Patients should be advised not to drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics, including VUITY. Patients should be advised to exercise caution in night driving and other hazardous activities in poor illumination.

Rare cases of retinal detachment and retinal tear have been reported with miotics, including VUITY. Individuals with pre-existing retinal disease are at increased risk. Therefore, examination of the retina is advised in all patients prior to the initiation of therapy. Patients should be advised to seek immediate medical care with sudden onset of flashing lights, floaters, or vision loss.

VUITY is not recommended to be used when iritis is present because adhesions (synechiae) may form between the iris and lens.

Contact lens wearers should be advised to remove their lenses prior to the instillation of VUITY and to wait 10 minutes after dosing before reinserting their contact lenses.

To prevent eye injury or contamination, care should be taken to avoid touching the dispensing bottle to the eye or to any other surface.

ADVERSE REACTIONS

The most common adverse reactions (>5%) reported in clinical trials were headache, conjunctival hyperemia, and eye irritation.

Please see full Prescribing Information.

US-VUI-230052